The findings of the present study corroborate with our earlier report of OPG as a marker of CV risks in diabetes, and in addition these findings indicate that TNF-α is a potential surrogate biomarker of CV risk in hypertensive patients with T2D on oral antidiabetic drugs. Here, TNFRSF11B is linked to type 2 diabetes mellitus.